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association with endoluminal repair of acute and
chronic thoracic aortic pathology
Brian G. Peterson, MD,a Mark K. Eskandari, MD, Thomas G. Gleason, MD, and
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Background: A rapidly increasing number of thoracic aortic lesions are now treated by endoluminal exclusion by using
stent grafts. Many of these lesions abut the great vessels and limit the length of the proximal landing zone. Various
methods have been used to address this issue. We report our experience with subclavian artery revascularization in
association with endoluminal repair of acute and chronic thoracic aortic pathology.
Methods: Thirty (43%) of 70 patients undergoing thoracic endovascular stent-graft placement from January 2001 to
August 2005 had lesions adjacent to or involving the origin of the subclavian artery. The mean age was 62 years (range,
22-85 years; 63% were men, and 37% were women). This subgroup of 30 patients had indications for repair that included
thoracic aortic aneurysm (n  15), traumatic transection (n  6), chronic dissection with pseudoaneurysm (n  5), and
acute dissection with intramural hematoma (n  4). All 30 patients had the subclavian origin covered by the stent graft.
In eight cases (27%), no effort was made to revascularize the subclavian artery before or during the endograft placement
procedure. Twenty-three (77%) of 30 patients underwent subclavian to carotid artery transposition (n  21) or bypass
(n 2) before (n 12; average of 14 days before stent-graft placement), concomitant with (n 10), or after (n 1) the
endovascular procedure. Physical examination and computed tomography scans were performed after surgery at 1, 6, and
12 months and annually thereafter. The mean follow-up was 18 months (range, 1-51 months).
Results: Five acute complications occurred in the eight patients (63%) who had the subclavian artery covered without
pre-endograft revascularization and included four patients who experienced stroke (accounting for the only death) and
one patient who developed symptomatic subclavian-vertebral steal that necessitated transposition 7 months later. Two
(9%) of the 23 patients who had subclavian revascularization experienced left-sided vocal cord palsies, and 1 patient (4%)
developed lower extremity paraparesis secondary to spinal cord ischemia. No late endoleaks related to retrograde sac
perfusion from the most distal great vessel have been identified in any patient.
Conclusions: Subclavian revascularization procedures can be performed with relatively low risk. Complications are rare,
and patient recovery is rapid. Although this is not necessary in all cases, we advocate subclavian to carotid transposition
when the aortic lesion is within 15 mm of the left subclavian orifice to prevent type II endoleak or perfusion of a dissected
false lumen when the ipsilateral vertebral artery is patent and dominant or when coronary revascularization using an
ipsilateral internal mammary artery is anticipated and in cases that necessitate extensive coverage of intercostals that
contribute to spinal cord perfusion. Carotid to subclavian artery bypass should be reserved for patients with a patent
internal mammary artery conduit perfusing a coronary vessel and should be combined with proximal subclavian ligation.
(J Vasc Surg 2006;43:433-9.)The first thoracic endografts are now commercially
available in the United States, and several others are under-
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tion trials.1 Significant proportions of patients with both
acute and chronic thoracic aortic disease who are evaluated
for treatment with endovascular therapy are found to have
pathology adjacent to the origin of the great vessels. Al-
though open surgical repair remains a viable treatment
alternative for many, management of such proximal disease
requires very proximal aortic cross-clamping and occasion-
ally hypothermic circulatory arrest to safely complete the
proximal anastomosis. When patients are considered for
endoluminal therapy, several different treatment paradigms
have developed for managing proximal thoracic aortic pa-
thology.2,3 When pathology abuts the left subclavian ar-
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of cerebrovascular and upper extremity blood flow with
subclavian-carotid transposition or bypass.4-8 Others advo-
cate simply ignoring this vessel and deploying the covered
portion of the stent graft over the subclavian origin.9-16
Branched and scalloped endografts are presently under
development, and techniques to fenestrate the endograft
material and deploy stents into the great vessels are being
pioneered in some institutions.17-19 There is no consensus
regarding how best to handle cases with proximal thoracic
aortic pathology. Most do agree that preventing significant
proximal endoleaks is critical for durable success and that
preserving vertebral andmammary circulation is important.
We studied a subset of patients who presented with aortic
pathology that was adjacent to the great vessels, in an
attempt to develop guidelines for managing these impor-
tant proximal aortic branches.
METHODS
Seventy patients (26 female and 44 male) underwent
repair of thoracic aortic pathology including aneurysm (n
38), acute dissection (n  5), traumatic disruption (n 
14), pseudoaneurysm (n  7), or intramural hematoma/
ulceration (n  6) at Northwestern Memorial Hospital
before August 2005. Industry-manufactured devices were
used in 38 cases, custom-fabricated grafts were used in 19
cases, and aortic extender cuffs designed for use in the
infrarenal aorta were deployed in 13 cases.
The proximal extent of the aortic pathology involved or
was adjacent to the great vessels in 30 (43%) of the 70
patients. This group included 19men (63%) and 11women
(37%) with an average age of 58 years (range, 26-81 years).
This subgroup of 30 patients had indications for repair that
included thoracic aortic aneurysm (n  15), traumatic
transection (n  6), chronic dissection with pseudoaneu-
rysm (n  5), and acute dissection with intramural hema-
toma (n  4). In all 30 cases, the most distal aortic branch
was covered by the proximal end of the stent graft.
At-risk subclavian vessels were managed by transposi-
tion into the adjacent common carotid artery before en-
dograft deployment in 20 patients and by carotid to sub-
clavian bypass with proximal subclavian ligation in 2
patients with an existing left internal mammary artery
(LIMA) to coronary bypass. Care was taken to maintain
antegrade or retrograde perfusion of all of the branches of
the subclavian. The artery was transposed, or bypassed, on
the same day that the endograft was placed, during the
same anesthetic but before device deployment in 10 pa-
tients. The subclavian(s) were transposed at a separate
operation before endograft placement in 12 patients (aver-
age, 14 days; range, 1-24 days before the endovascular
procedure). This included 2 patients with aberrant right
subclavian vessels who had both the right and left subcla-
vian vessels transposed at separate settings before surgery
(for a total of 24 subclavian vessels revascularized before
endograft placement). All 22 patients then went on to have
the subclavian artery origin covered by the stent graft, with
successful obliteration of antegrade flow into the subclavianstump. One of the 22 patients who had preoperative sub-
clavian transposition had the subclavian origin covered with
the stent graft and the left common carotid artery covered
with a proximal bare metal stent.
Eight patients had a nonrevascularized subclavian ori-
gin covered by the proximal end of the stent graft, and no
Fig 1. A, Contrast-enhanced computed tomography scan dem-
onstrating aneurysmal degeneration of the descending thoracic
aorta. B, Corresponding intraoperative angiogram.attempt was made to reconstruct the branch vessel before
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group, counted below as the 23rd revascularized patient,
required subclavian artery to common carotid artery trans-
position 7 months after endograft placement. This patient
is discussed in more detail in the next section.
Data were maintained prospectively in an institution-
specific database as well as in alternate databases kept as
mandated by our industry partners during phase II trials.
This information was then reviewed retrospectively from
these prospectively maintained databases according to
guidelines indicated by the Northwestern University Med-
Fig 2. A, Contrast-enhanced computed tomography scan of the
chest demonstrating an acute traumatic transection of the descend-
ing thoracic aorta. B, Corresponding intraoperative angiogram.ical School Institutional Review Board.All patients underwent a thorough physical examina-
tion, including bilateral upper extremity blood pressure
measurements and determination of the ankle-brachial in-
dex, before surgery, after surgery in the recovery room, and
daily during the hospitalization. Outpatient follow-up con-
sisted of an evaluation at 1, 6, and 12 months and yearly
thereafter. Twenty-seven (90%) of 30 patients in whom the
proximal extent of the aortic pathology involved or was
adjacent to the great vessels attended a 1-month follow-up,
where they underwent a complete physical examination
with determination of the ankle-brachial index, plain chest
radiographs, and a chest computed tomography scan. Of
the 13 eligible patients, 10 (77%) have attended the
6-month follow-up, and 5 have been re-examined 1 year or
more after treatment.
RESULTS
One (1.4%) of the 70 patients died within 30 days of
surgery from stroke. This patient is described in more detail
below. Additional periprocedural complications directly re-
lated to endograft therapy included four (6%) more strokes,
two (3%) cases of access site limb ischemia, two (3%) cases of
spinal cord ischemia with paraparesis, two (3%) retroperi-
toneal bleeds, and, as previously noted, one (1%) case of
symptomatic subclavian steal. Five (7%) late deaths have
occurred: from sepsis (n  1), perforated viscus (n  1),
and congestive heart failure (n 1) and after open ascend-
ing aortic aneurysm repair (n  2).
Eight (27%) early complications developed in the sub-
group of 30 patients with proximal thoracic pathology. Five
(63%) complications occurred in the eight patients who had
Fig 3. Intraoperative angiogram demonstrating pseudoaneurysm
formation of the descending thoracic aorta in the setting of a
chronic aortic dissection.the nontransposed subclavian origin covered at the time of
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developed symptoms of subclavian-vertebral steal, includ-
ing arm fatigue/pain and syncope, shortly after endograft
placement and left subclavian coverage. The symptoms did
not resolve with time, and this patient required subclavian
revascularization via subclavian to carotid transposition 7
months after the endograft procedure for treatment of
ongoing posterior circulation ischemia. Four patients expe-
rienced stroke. One of the four patients developed a large
left middle cerebral distribution infarct, likely due to athe-
roembolization from the aortic arch, and died within days
of the endograft placement. Three patients developedmag-
netic resonance imaging–confirmed posterior circulation
strokes. In two of these cases, the infarcts were confined to
the distribution of the posterior circulation and ipsilateral
to the covered subclavian artery. Upon further review of
available imaging, the contralateral vertebral artery was
absent in both cases. The third patient had multiple, small,
bilateral anterior and posterior circulation infarcts, again
likely due to diffuse atheroembolization. To date, no other
patients have voiced significant complaints related to arm
or brain ischemia. Furthermore, no late endoleaks resulting
from retrograde subclavian flow have been identified.
Among the 21 patients undergoing 23 (including 2
staged, bilateral procedures in the patients with aberrant
Fig 4. Magnetic resonance imaging of the brain demonstrating
an isolated left posterior circulation infarction.anatomy) subclavian to carotid artery transposition proce-dures before or after endograft placement and the 2 pa-
tients who had pre-endograft carotid-subclavian bypass,
there were 2 (8%) complications directly related to the
subclavian revascularization procedure. Both were tempo-
rary left-sided vocal cord palsies, and both were assumed to
be related to traction on the vagus and/or recurrent nerve
during the revascularization procedure. The paralyzed vo-
cal cords were confirmed by indirect laryngoscopy. There
was spontaneous clinical resolution of one palsy after 3
months. The second patient underwent successful vocal
cord medialization 6 weeks after the event. A third patient
from this group experienced delayed spinal cord ischemia
and lower extremity paraparesis after endograft placement
that was unrelated to the subclavian revascularization.
There were no strokes or procedure-related deaths in this
group. All 23 subclavian to carotid artery transpositions
and both bypass grafts remain patent at a mean follow-up of
18 months (range, 1-51 months). No late morbidity re-
lated to these procedures has occurred. In all transposition
cases, the subclavian stump(s) have thrombosed. In one of
two bypass cases, the subclavian was seen on computed
tomography to fill retrograde all the way to the device,
although no type II leak could be identified.
A single stroke occurred in the group of 40 patients
with thoracic aortic pathology distal to the great vessels. In
this group of patients, in whom the endograft device was
deployed well beyond the aortic arch and no manipulation
of the great vessels was necessary, the stoke rate was lower
Fig 5. Angiographic appearance of a completed left subclavian
artery to left common carotid artery transposition with contrast
filling the residual subclavian stump.than it was in the 30 patients with pathology adjacent to the
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statistical significance (P  .15).
DISCUSSION
Thoracic endografts are undergoing refinement in
phase II and postmarketing trials in the United States.1
Industry-manufactured devices have been or are currently
being tested for treatment of thoracic aortic aneurysms.
The first of these devices, the Gore Thoracic Excluder
(W.L. Gore & Associates, Inc., Tempe, AZ), has recently
gained approval from the Food and Drug Administration
to treat aneurysmal pathology. These industry-manufac-
tured devices, some custom-made devices, and extender
cuffs designed for use in the infrarenal aorta have been used
off-label or with physician-sponsored investigational device
exemptions to treat acute dissections, solitary aortic ulcers,
and traumatic transections in the United States.
Although various types of pathology, and certainly
some aneurysms, may abut the left subclavian artery, cer-
tain disease processes—namely, traumatic transection and
dissection—nearly always develop within close proximity to
the origin of the great vessels. In our experience, 30 (43%) of
70 patients undergoing endovascular repair of acute or
chronic thoracic aortic pathology had lesions that were adja-
cent to or involved the origin of the great vessels. This under-
scores the importance of being able to safely position endolu-
minal devices high in the descending thoracic aorta or even
with extension into the aortic arch if we are to use endovascu-
lar techniques to treat these lesions. Alternative treatment
paradigms have been devised to address proximal aortic pa-
thology involving the great vessels, but only some include
techniques to maintain normal perfusion to the head and
arms. An informal review of a random segment of the current
endograft literature showed a combined 23% complication
Table. Summary of the current literature, demonstrating
of the left subclavian orifice by a thoracic endograft as com
artery was revascularized
Study
Proximal
aortic cases
Subclavian
covered Outcom
Mitchell20 13 2 1 Neurologic 
Grabenwoger8 9 0 No complication
Moore15 1 0 No complication
Hausegger10 6 4 No complication
Cambria13 6 0 No complication
Criado2 13 5 No complication
Criado3 9 2 No complication
Gorich9 22 21 4 neurologic, 4 
Heijman7 5 0 No complication
Burks16 3 1 No complication
Tiesenhausen11 10 8 3 neurologic, 2 
Lambrechts14 7 6 No complication
Hutton21 1 1 1 neurologic 
Hansen22 4 4 No complication
Leurs23 79 42 1 neurologic 
Northwestern 30 8 4 neurologic, 1
Totals 218 104 24 (23%)rate when the left subclavian artery orifice was covered, com-pared with a 3% complication rate when flow into the left
subclavian artery was preserved. The difference in neurologic
outcome is most noteworthy (Table).2,3,7-11,13-16,20-23
Several published series have specifically addressed the
topic of proximal thoracic aortic pathology, but it seems
that no consensus has arisen on how best to treat these
patients. Some groups have sought to lengthen the proxi-
mal landing zones via transposition procedures, whereas
others have advocated carotid to carotid, femoral to sub-
clavian, or carotid to subclavian bypass.4-8 Although the
bypass procedures may address the issue of lengthening the
proximal neck to ensure an adequate seal zone, they gen-
erate the potential for type II endoleak and continued
perfusion of the sac in the setting of aneurysmal disease or
of the false lumen in the case of dissection. Other groups
have demonstrated success with techniques designed to
maintain normal branch perfusion with scallop-edged and
bare metal–ended stent grafts or with endograft fenestra-
tion and retrograde stent deployment.15,16,19,24 Although
they are novel solutions, these techniques clearly add a new
level of complexity to endovascular aortic repair. Branched
endovascular prostheses are presently being developed,
but, again, these advancements make device deployment
more intricate, and widespread acceptance is likely a few
years away.17,18
Perhaps the added complexity of branch vessel manage-
ment is unnecessary and coverage of the great vessel ori-
gins, at least the left subclavian, can be routinely performed
with impunity. Indeed, some groups have suggested that
coverage of the left subclavian artery is safe and well toler-
ated and that extra-anatomic bypass or transposition should
be reserved only for patients who develop symptoms that
necessitate intervention.9-16 Clearly there are real advan-
tages to coverage without perioperative great vessel revas-
complication rate in patients who underwent coverage
d with a 3% complication rate when the left subclavian
mplications
Subclavian
transposed Outcome/complications
11 No complications
9 No complications
1 No complications
2 No complications
6 No complications
8 1 lymphatic
7 No complications
eaks, 2 arm, 1 spinal 1 No complications
5 No complications
2 No complications
eaks 2 No complications
1 No complications
0 No complications
0 No complications
37 No complications
22 2 recurrent nerve injuries
114 3 (3%)a 23%
pare
e/co
s 
s 
s 
s 
s 
s 
endol
s 
s 
endol
s 
s 
armcularization. In the setting of traumatic aortic transection
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is mandated, an added procedure before emergent life-
saving endovascular intervention may be prohibitive. Addi-
tionally, much to the dismay of some groups, although
appealing to others, the services of a vascular surgeon and
the availability of an operating room, both necessary for
performing bypass or transposition procedures, would not
be required. In several instances, our patients underwent an
additional anesthetic for the transposition procedure, but
in most cases this can be eliminated if the open and endo-
vascular procedures are performed concomitantly.
Despite the potential advantages of simplifying the
thoracic endorepair, our experience has led us to advocate,
in certain situations and with particular anatomic findings,
the rerouting of great vessel blood flow before endoluminal
repair of thoracic aortic lesions is undertaken. In fact, in our
series, five of eight patients who were treated by simply
covering the subclavian origin without revascularization
developed adverse events. Four of these events were strokes
that occurred in the immediate postoperative period. Al-
though we cannot state with certainty that these could have
been prevented by antecedent transposition, and although
one certainly could argue that proximal disease is simply a
marker for increased stroke risk overall, two isolated poste-
rior circulation events would certainly suggest that ipsilateral
vertebral perfusion remains critical. The fifth patient, who
required late subclavian revascularization for persistent poste-
rior circulation symptoms, adds credence to this concern.
In cases of proximal thoracic aortic pathology arising
within 15 mm of the most distal great vessel, especially
when the dominant vertebral artery (the vertebral con-
tralateral to one that is hypoplastic or absent or ends
prematurely in a cerebellar branch without contributing to
the basilar artery) arises from the ipsilateral subclavian
vessel, prophylactic branch revascularization should be
considered before endovascular repair. The ability to main-
tain normal perfusion and prevent ischemia of the upper
extremity via the subclavian and of the brainstem via the
ipsilateral vertebral artery are obvious benefits. We also use
pre-endograft subclavian revascularization when multi-
ple intercostal vessels will be covered in patients with
extensive descending thoracic aortic pathology. This may,
in theory, help protect against spinal cord ischemia by
preserving important vertebral artery collaterals that con-
tribute to spinal blood flow. Patients who may undergo
future coronary revascularization with a LIMA should un-
dergo transposition to preserve antegrade flow into the
coronary bypass conduit. Patients who have already had
LIMA reconstruction require carotid to subclavian bypass
(rather than transposition, because this requires unsafe
clamping proximal to the LIMA) when the origin of the
subclavian is to be covered. Finally, patients with very
proximal aneurysms or type B dissections may require
definitive management of the great vessels to prevent type
II endoleak or continued perfusion of a dissected false
lumen from retrograde subclavian blood flow. This should
be accomplished by subclavian transposition proximal to
any branches to eliminate all retrograde perfusion. Alterna-tively, if a carotid to subclavian bypass is chosen, the sub-
clavian origin must be endoluminally occluded or ligated
proximal to any branches for the same reason.
We prefer transposition over bypass because it is the
most logical approach in most cases. First, the addition of
the proximal subclavian artery ligation that is necessary to
eliminate endoleak potential after bypass requires the same
exposure as transposition. Unlike with a bypass, the expo-
sure for transposition, when properly performed, does not
risk injury to the phrenic nerve, and transposition avoids
the use of a prosthetic conduit in the neck. Finally, trans-
position is a more durable reconstruction when compared
with bypass. In addition to the 100% patency rates at
18-month follow-up in this series, the safety, efficacy, and
superior durability of subclavian to carotid transposition are
well established.25,26
Although perhaps not necessary in every case, subcla-
vian revascularization provides some advantages over great
vessel coverage, and in the 22 patients in this series in whom
subclavian transposition(s) or bypass preceded endograft
placement and in the single patient who had the delayed
transposition, the procedure(s) were well tolerated. The
risks associated with subclavian transposition in experi-
enced hands are low, and the advantages over carotid to
subclavian bypass are real.25,26 However, when great vessel
revascularization is desired and transposition is contraindi-
cated, a bypass should be considered rather than simply
covering the great vessel origins.
At this time, in semiurgent and elective proximal tho-
racic cases, when time permits, we elect to image supra-
aortic trunk and extracranial and intracranial cerebrovascu-
lature before endorepair. We prefer magnetic resonance
angiography, but computed tomography and vascular ul-
trasonography may also suffice. When there are indications
for great vessel revascularization, as outlined previously, we
proceed with elective transposition immediately before en-
dorepair. Bypass is rarely used. In truly emergent cases, we
attempt to visualize all the supraaortic trunks at the time of
the intraoperative predeployment angiogram, accept the
risk, and deploy the device across the subclavian. We will
then transpose the vessel on a later date as clinical circum-
stances suggest.
CONCLUSION
The ability to provide minimally invasive endovascular
treatment for acute and chronic thoracic aortic diseases
seems to hold great promise. Optimal and appropriate
management of arch vessels in cases that involve proximal
descending aortic pathology should minimize unnecessary
ischemic complications and help provide for a more durable
repair.
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